يمكنكم ارسال مقالاتكم عبر البريد الالكتروني jscience@ush.sd

العدد الرابع

Immunohistochemical detection of Bcl-2 expression in prostatic cancer and benign prostatic hyperplasia among Sudanese patients: Original article

Ahmed Mohamed Ahmed Ibrahim , Elkhawad Eisa Abdel Rahman, Mohammed Awed ElkareemAbdelgadir Elzaki

Ahmed Mohamed Ahmed Ibrahim* , Elkhawad Eisa Abdel Rahman*, Mohammed Awed Elkareem Abdelgadir Elzaki*
* Department of Histopathology and Cytology, Faculty of Medical Laboratory Sciences, Shendi University, Shendi, Sudan, *drlukashendi220@gmail.com

Download Paper | تحميل الموضوع

Abstract

The study aims to detect the expression of B-cell lymphoma 2 (Bcl-2) protein in prostatic cancer and benign prostatic hyperplasia (BPH), which is an important anti-apoptosis factor that is also capable of inhibiting cell proliferation via cell division cycle, the study deals with genetic underline cause of prostate tumor, among Sudanese patients using immunohistochemistry technique. Tissue Microarray (TMA) of forty prostatectomy samples selected from paraffin-blocks previously diagnosed as prostatic carcinoma and other forty as BPH. The age of the patients ranged from 50 to 80 years. The study reveals weak expression in the samples of BPH. However, all prostatic carcinoma expressed Bcl-2, either glandular sub-epithelial and/or intermural, strongly positive in 40% of samples, moderately expressed in 22.5%, and weakly expressed in 37.5%. A significant correlation found between Bcl-2 expression and the Gleason score of prostatic carcinoma indicated that the expression of Bcl-2 increased with tumor grade. The Bcl-2 has been expressed in prostatic carcinoma with different grades and is weakly expressed in BPH. In conclusion, the Bcl-2 expressions can be involved in the pathogenesis of the prostatic adenocarcinoma and in BPH; Bcl-2 expression protein can use for prostatic adenocarcinoma as a prognostic marker.

Keywords: Bcl-2, BPH, prostate carcinoma

زر الذهاب إلى الأعلى